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Summary
Insulin is viewed as a positive regulator of fatty acid synthesis by increasing fatty acid synthase (FAS) mRNA transcription.
We uncover a new mechanism by which insulin acutely reduces hepatic FAS activity by inducing phosphorylation of the
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and its interaction with FAS. Ceacam1 null mice
(Cc1−/−) show loss of insulin’s ability to acutely decrease hepatic FAS activity. Moreover, adenoviral delivery of wild-type,
but not the phosphorylation-defective Ceacam1 mutant, restores the acute effect of insulin on FAS activity in Cc1−/−
primary hepatocytes. Failure of insulin to acutely reduce hepatic FAS activity in hyperinsulinemic mice, including L-SACC1
transgenics with liver inactivation of CEACAM1, and Ob/Ob obese mice, suggests that the acute effect of insulin on FAS
activity depends on the prior insulinemic state. We propose that this mechanism acts to reduce hepatic lipogenesis
incurred by insulin pulses during refeeding.Introduction
The carcinoembryonic-related cell adhesion molecule, CEA-
CAM1, is a transmembrane glycoprotein expressed in liver but
not in muscle and adipose tissue. It is phosphorylated by the
insulin receptor (IR) kinase on Tyr488 in its cytoplasmic tail, and
this phosphorylation requires an intact Ser503 residue (Najjar
et al., 1995). When phosphorylated, CEACAM1 promotes insu-
lin clearance by increasing receptor-mediated insulin uptake
into endocytotic vesicles (Formisano et al., 1995; Li Calzi et
al., 1997).
Biochemical evidence for a role of CEACAM1 in insulin clear-
ance is buttressed by studies of L-SACC1 transgenic mice with
inactivation of CEACAM1 in liver. These mice develop impaired
insulin clearance, hyperinsulinemia, insulin resistance, visceral
obesity with increased plasma free fatty acids (FFA), and dys-
lipidemia, including elevated plasma and hepatic triglyceride
content (Poy et al., 2002b). Increased visceral obesity and
chronically elevated FFA output contribute to altered insulin
metabolism in L-SACC1 mice (Dai et al., 2004).
Chronically elevated levels of insulin increase the levels in
liver of lipogenic enzymes, including fatty acid synthase (FAS)
and acetyl-CoA carboxylase (ACC) (Assimacopoulos-Jeannet
et al., 1995; Bazin and Lavau, 1982; Shillabeer et al., 1992).
This promotes hepatic lipogenesis and increases VLDL-triglyc-
eride output and compensatory insulin secretion, which in turn
leads to increased visceral adiposity. Thus, altered fat metabo-
lism in liver could play a role in the pathogenesis of visceral
obesity and insulin resistance in L-SACC1 mice. Growing evi-CELL METABOLISM : JULY 2005 · VOL. 2 · COPYRIGHT © 2005 ELSEVIdence supports a central role for de novo synthesis of fatty
acids (FA) and increased hepatic VLDL-triglyceride output in
the pathogenesis of obesity and insulin resistance (McGarry,
2002; Zammit, 2002). In fact, mice overexpressing malonyl-
CoA decarboxylase, the enzyme that degrades the malonyl-
CoA pool that is routed to FA synthesis by FAS, exhibit in-
creased insulin sensitivity and loss in body weight (An et al.,
2004).
ACC converts acetyl-CoA to malonyl-CoA, which is in turn
converted to saturated long-chain fatty acids by FAS (Wakil,
1989). Together with exogenous FA, these are converted to
long-chain fatty acyl-CoA (LCFA-CoA) that may undergo β-oxi-
dation or esterification to triglycerides or to phospholipids. In
addition to its role as FAS substrate, malonyl-CoA inhibits car-
nitine palmitoyltransferase 1 (CPT1) to reduce mitochondrial
fatty acid β-oxidation (Ruderman et al., 1999) and promote gly-
colysis (Randle, 1998). The sensitivity of CPT1 to malonyl-CoA
is regulated by nutritional and hormonal factors (McGarry,
2002; Zammit, 2002). For instance, starvation increases fatty
acid oxidation and gluconeogenesis in liver. Recovery of the
sensitivity of CPT1 to malonyl-CoA progresses slowly upon re-
feeding despite rapid insulin surges to replete the glycogen
stores (Shulman and Landau, 1992). In contrast, hepatic tri-
glyceride output undergoes a rapid decrease by early insulin
surges in refed normoinsulinemic (Malmstrom et al., 1998), but
not hyperinsulinemic, humans (Lewis and Steiner, 1996). The
mechanism of reduction in triglyceride secretion in response to
acute insulin pulses has not been identified (Zammit, 2002).
Because FAS and ACC are key enzymes in the de novo syn-ER INC. DOI 10.1016/j.cmet.2005.06.001 43
A R T I C L Ethesis of FA, which essentially regulates the rate of hepatic tri-
glyceride output, it is reasonable to hypothesize that insulin
exerts its rapid effect on triglyceride secretion by acutely regu-
lating FAS and ACC activity. Acutely, insulin activates ACC to
promote malonyl-CoA synthesis via inhibiting AMP-activated
protein kinase (Kim et al., 1989; Witters and Kemp, 1992), and
the role of this regulation in energy balance and metabolism
has been well documented (Kahn et al., 2005). In contrast to
its positive long-term effect on FAS transcription (Fukuda et al.,
1999; Paulauskis and Sul, 1989; Stapleton et al., 1990), acute
regulation of FAS activity by insulin has not been described.
Moreover, regulation of FAS by phosphorylation has not been
well demonstrated. Direct phosphorylation of FAS by a serine/
threonine kinase and indirectly through the activity of a phos-
phatase has been observed in mammary tumors (Hennigar et
al., 1998).
In humans, FAS is expressed at high levels in liver and at
lower levels in intra-abdominal adipose tissue, lungs, and
mammary glands (Semenkovich, 1997). The superior hepatic
FAS levels have been in part attributed to higher insulin levels
in the portal circulation (Ward et al., 1990). Despite its high
levels, hepatic FAS activity is not remarkable under physiologic
conditions. In contrast, FAS activity is elevated in hyperinsuli-
nemic, hypertriglyceridemic, and obese rodents (Assimacop-
oulos-Jeannet et al., 1995; Bazin and Lavau, 1982; Shillabeer
et al., 1992). Conversely, treatment of obese mice with FAS
inhibitors reduces body weight independently of leptin (Loftus
et al., 2000). This suggests that downregulation of hepatic FAS
activity plays an important role in regulating visceral adiposity
and hepatic insulin action. We herein report that in normoinsuli-
nemic states, acute rise in insulin levels reduces hepatic FAS
activity by inducing CEACAM1 phosphorylation and binding
to FAS.
Results
In vitro analysis of CEACAM1/FAS interaction
Using a phosphorylated CEACAM1 intracellular peptide as a
probe to screen an expression library (Macgregor et al., 1990),
we isolated three clones encoding the thioesterase domain and
the acyl-carrier domains of FAS (nucleotides 6815–9136, ac-
cession number M76767) (Amy et al., 1989).
To investigate the CEACAM1/FAS interaction, we employed
GST pull-down assays with peptides from the intracellular tail
of wild-type (wt) and mutant CEACAM1 (Choice et al., 1998).
In vitro phosphorylated fusion peptides were incubated with
purified His-tagged recombinant FAS (Figure 1A) or with ex-
tracts from MDA-MB 468 breast cancer cells, which express
FAS at high levels (Figure 1B). Recombinant insulin receptor
kinase (IRKβ) increased phosphorylation of wt CEACAM1 (wt
CC1) (Figure 1A, center, lane 4 versus lane 3) and elevated the
level of its association with recombinant FAS, as demonstrated
by immunoblotting (Ib) GST pellets with α-FAS antibody (Figure
1A, top, lane 4 versus lane 3). The absence of FAS in the GST
control pellet (Figure 1A, top, lanes 1 and 2) indicates that the
binding between FAS and the intracellular domain of CEA-
CAM1 is specific. Similarly, IRKβ increased binding between
the intracellular domain of wt CC1 and FAS derived from MDA-
MB 468 lysates (Figure 1B, top, lane 4 versus lane 3). The in-
crease in CEACAM1/FAS binding corresponded to increased
CEACAM1 phosphorylation by IRK (Figure 1B, center, lane 4β
44versus lane 3). As previously shown (Choice et al., 1998), IRKβ
phosphorylated the Y513F CEACAM1 peptide (Figure 1B, cen-
ter, lane 10 versus lane 9). This, in turn, was correlated with an
increased amount of FAS in the GST pellet (Figure 1B, top, lane
10 versus lane 9). The specificity of this binding is demon-
strated by the failure of FAS to bind the GST moiety in control
samples (Figure 1B, top, lanes 1 and 2). Consistent with our
previous observations (Najjar et al., 1995), mutating Ser503 to
Ala inhibited CEACAM1 phosphorylation by IRKβ (Figure 1B,
center, lanes 8 versus lane 7 and 14 versus 13). Moreover, this
mutation prevented the increase in CEACAM1 binding to FAS
by IRKβ (Figure 1B, top, lane 8 versus 7 and 14 versus 13). In
contrast, a Ser to Asp503 mutation preserved the ability of
IRKβ to induce CEACAM1 phosphorylation (Figure 1B, center,
lane 16 versus lane 15) and increase its binding to FAS (Figure
1B, top, lane 16 versus 15). Mutating Tyr488 to Phe, individu-
ally or in combination with Tyr513, prevented CEACAM1 phos-
phorylation (Figure 1B, center, lane 6 versus lane 5 and 12 ver-
sus 11) and the increase in its binding to FAS in the presence
of IRKβ (Figure 1B, top, lanes 5 and 6 and 11 and 12). IRKβ
did not phosphorylate His-tagged FAS even after 60 min (not
shown), suggesting that FAS was not phosphorylated by IR.
These data propose that CEACAM1 phosphorylation by IR is
required for its binding to FAS. Although the identification of
FAS in a screen with a CEACAM1 probe is consistent with di-
rect binding of CEACAM1 to FAS, we cannot rule out an indi-
rect association between these proteins.
CEACAM1/FAS interaction in intact cells
To further investigate CEACAM1/FAS association, we carried
out coimmunoprecipitation experiments in H35-BT cells, which
express high levels of insulin receptors, FAS and CEACAM1
(Figure 2A). To this end, we immunoprecipitated (Ip) cell lysates
with α-CC1 rat monoclonal antibody and analyzed immunore-
active proteins by immunoblotting with α-FAS (Figure 2A, top)
or α-phosphotyrosine (α-pTyr) antibody (Figure 2A, bottom). To
normalize for the amount of CEACAM1, membranes were re-
probed with α-CC1 rat polyclonal antibody (Figure 2A, bottom).
As previously reported (Najjar et al., 1995), CEACAM1 phos-
phorylation by the insulin receptor was observed 2 min after
initiation of insulin treatment and progressively increased to
reach a maximum after 5–10 min of treatment (Figure 2A, bot-
tom). Coimmunoprecipitation analysis revealed that subse-
quent to initiation of its phosphorylation, CEACAM1 becomes
associated with FAS, reaching a maximum at 7–10 min of stim-
ulation with insulin and decreasing progressively during pro-
longed treatment for up to 90 min (Figure 2A, top). In contrast
to FAS, CEACAM1 did not bind ACC in the absence or pres-
ence of insulin (not shown). These data indicate that in re-
sponse to short-term treatment with insulin, CEACAM1 phos-
phorylation by the insulin receptor precedes its binding to FAS.
Internalization of CEACAM1 in response to insulin
To examine how the plasma-membrane protein CEACAM1 as-
sociates with the cytoplasmic protein FAS, we examined by
confocal microscopy the internalization of CEACAM1 in rat
hepatoma H4-II-E cells, derivatives of H35 cells, in the pres-
ence or absence of insulin. In the absence of insulin, CEA-
CAM1 was distributed largely on the plasma membrane (Figure
2B, green stain—Insulin) as FAS was typically localized to the
cytoplasmic region (Figure 2B, red dye). As evidenced by theCELL METABOLISM : JULY 2005
Regulation of FAS activity by insulinFigure 1. Insulin amplifies CEACAM1 binding to
FAS in vitro
A and B) GST intracellular peptides of CEACAM1
(CC1int) were incubated with (+) or without (−) IRKβ
in the presence of [γ-32P] ATP. Peptide-free GST was
included as control to account for nonspecific asso-
ciation. Phosphorylated GST peptides were allowed
to bind to purified His-FAS protein (A) or to cell ly-
sates from MDA-MB 468 cells (B). The Sepharose
pellets were analyzed by 6%–12% SDS-PAGE and
immunoprobing with α-FAS antibody to examine
FAS association with CEACAM1 (top). Phosphory-
lated CC1 (pCC1) was detected by autoradiography
(center). The amount of GST peptides was mea-
sured by Ponceau S staining (bottom). Gels are rep-
resentatives of at least three experiments.minimal amount of overlap between the two fluorophores,
CEACAM1/FAS colocalization was negligible in the absence of
insulin (Figure 2B). Moreover, insulin treatment did not notice-
ably alter FAS distribution (Figure 2B). Instead, it stimulated the
progressive cytoplasmic redistribution of CEACAM1 (Figure
2B), as evidenced by the higher than 90% localization of the
green fluorophore in the cytoplasm and the merging of the flu-
orophores after 15–60 min of insulin treatment. Similar experi-
ments using green FITC labeling revealed that, like FAS, the
cytoplasmic distribution of insulin receptor substrate-2 (IRS-2)
was comparable in insulin-treated and untreated cells (Figure
2B). This suggests that insulin treatment did not generally alter
the cellular distribution of proteins under our experimental con-
ditions and that its effect on CEACAM1 translocation into the
cell is specific. The data propose that CEACAM1/FAS inter-
action requires CEACAM1 transport inside the cell, probably
via clathrin-coated vesicles, as we have previously reported
(Choice et al., 1998). The data are consistent with the notion
that CEACAM1 phosphorylation precedes its cellular uptake
and that this in turn promotes its binding to FAS.
Effect of CEACAM1/FAS interaction on FAS activity
Next, we treated H35-BT cells with insulin for 0–90 min and
investigated the effect of CEACAM1 association on FAS activ-
ity. As Figure 3A reveals, short-term insulin treatment decreased
FAS activity, reaching a maximum effect by 15 min. Reversal
of this effect occurred by 60 min, as the ability of insulin to
induce CEACAM1 phosphorylation and its association with
FAS was reduced (Figure 2A). This suggests that the effect of
insulin is mediated by CEACAM1 phosphorylation. To investi-
gate whether CEACAM1 phosphorylation is sufficient, we incu-
bated His-tagged CEACAM1 purified from Sf9 insect cells
(Phan et al., 2001) with IRKβ or buffer alone prior to the addi-
tion of purified His-FAS. FAS activity was assayed and nor-
malized per activity in the absence of CEACAM1, and the re-CELL METABOLISM : JULY 2005maining activity was plotted against CEACAM1 concentration
(Figure 3B). As Figure 3B reveals, 250–500 pmol CEACAM1
reduced FAS activity by w50% in the presence but not in the
absence of IRKβ. This suggests that CEACAM1 phosphoryla-
tion is required to mediate the acute inhibition of FAS by in-
sulin.
Acute effect of insulin on FAS activity in vivo
To investigate whether insulin downregulates FAS activity
acutely in vivo, we fed overnight-fasted mice with glucose by
gavage for 0–120 min (Figure 4A). Mirroring the biphasic in-
crease in insulin secretion in response to glucose (Figure 4A,
top graph), hepatic FAS activity underwent a biphasic decrease
at 2 and 30–120 min post-glucose administration (Figure 4A,
center graph). In contrast, this treatment had no effect on FAS
activity in adipose tissue (Figure 4A, bottom graph). The ability
of insulin to decrease hepatic FAS activity was paralleled by its
ability to induce phosphorylation of the insulin receptor (pIR),
as detected by immunoblotting the IR immunopellet (Ip) with
α-pTyr antibody (Figure 4A, center gel set), and of CEACAM1
(pCC1) (Figure 4A, top gel set). As expected, CEACAM1 phos-
phorylation led to its increased interaction with FAS, as de-
tected by coimmunoprecipitation (top gel set). The amount of
FAS remained constant under these conditions (bottom gel
set). This suggests that the acute effect of insulin on FAS activ-
ity depends on CEACAM1 phosphorylation rather than FAS
content.
We further tested the acute effect of insulin on hepatic FAS
activity in vivo by feeding overnight-fasted mice regular chow
for 1–10 hr. As Figure 4B reveals, insulin secretion was elevated
at 1, 4, and 7 hr of refeeding, but more significantly at 4 and 7
hr (top graph), by comparison to fasted mice (F). FAS activity
was reduced at 4 and 7 hr of refeeding in the liver (center
graph) but not in the adipose tissue (bottom graph). Ad libitum
randomly fed mice (Rand) exhibited no difference in hepatic45
A R T I C L EFigure 2. Insulin amplifies CEACAM1 binding to FAS in intact cells
A) H35-BT cells were serum-starved, treated without (0) or with insulin (100 nM)
for 2–90 min, and lysed prior to immunoprecipitating (Ip) 100 g of proteins with
α-CC1 antibody for analysis by 6% SDS-PAGE and immunoblotting (Ib) with
α-FAS antibody to detect coimmunoprecipitated FAS (top) and α-pTyr antibody
to detect phosphorylated CEACAM1 (pCC1) (bottom). The latter was reprobed
with α-CC1 antibody to account for the amount of CEACAM1 in the immunopel-
lets (bottom). Gels are representatives of at least three experiments.
B) H4-II-E cells were serum-starved, incubated with α-CC1 monoclonal antibody,
and fixed immediately (− insulin) or after incubation with insulin at 37°C from
5–60 min. Following incubation with polyclonal α-FAS antibody, cells were incu-
bated with goat anti-mouse FITC and goat anti-rabbit Cy3 conjugated secondary
antisera and analyzed by confocal microscopy. For IRS-2 detection, serum-
starved cells were treated with (+) or without (−) insulin for 30 min, fixed, blocked,
incubated with α-IRS-2 antibody, and labeled with green FITC.46Figure 3. Short-term treatment with insulin reduces FAS activity
A) Serum-starved H35-BT hepatoma cells were treated with insulin for 0–90 min.
FAS enzymatic activity was assayed by [14C]-malonyl-CoA incorporation in tripli-
cate as described in Experimental Procedures. Values are expressed as mean ±
SEM. *p < 0.05 versus untreated. For simplicity, the x axis is not drawn to scale.
B) 0–500 pmol of purified His-CEACAM1 was phosphorylated by GST-IRKβ (solid
bars) or buffer (white bars). Thereafter, 1 pmol of His-FAS was added at 4°C for
60 min and FAS activity was assayed by [14C]-malonyl-CoA incorporation in tripli-
cate samples as described in Experimental Procedures and normalized per activ-
ity in the absence of CEACAM1. Values are expressed as mean ± SEM.
*p < 0.05 versus 0–100 pmol CEACAM1.FAS activity by comparison to fasting. The decrease in hepatic
FAS activity occurred when CEACAM1 phosphorylation (pCC1)
and association with FAS significantly increased in response to
insulin (top gel set) and despite a modest increase in FAS pro-
tein content after 5 hr of refeeding (bottom gel set). Interest-
ingly, the low level of insulin secreted at 1 hr of refeeding in-
duced a modest receptor phosphorylation (pIR) (center gel set)
but was not sufficient to trigger a significant increase in CEA-
CAM1 phosphorylation and coimmunoprecipitation with FAS.
The acute effect of insulin on FAS activity depends
on the insulinemic state
In order to examine the effect of the prior insulinemic state on
the acute effect of insulin on FAS activity, we subjected the
hyperinsulinemic insulin-resistant L-SACC1 transgenic mice to
a fasting/refeeding paradigm similar to the one described
above. Insulin secretion peaked at 2 hr and started to rise again
at 5 hr of refeeding (Figure 5A, top graph). In contrast to normalCELL METABOLISM : JULY 2005
Regulation of FAS activity by insulinFigure 4. Insulin acutely decreases hepatic FAS activity in vivo
A) Two-month-old male mice were fasted overnight and given glucose by gavage for 0–120 min prior to drawing whole blood at indicated time points from retro-orbital
sinuses to determine plasma insulin levels (top graph) and removal of liver and white adipose tissue (AT) (center and bottom graph, respectively) to assay FAS enzymatic
activity by [14C]-malonyl-CoA incorporation, as described in Experimental Procedures. Three to five mice were analyzed per time point and FAS assay was performed
in quadruplet. Values are expressed as mean ± SEM. *p < 0.05 versus fasted (0). For simplicity, values on the x axis were not to scale. Liver lysates were immunoprecipi-
tated (Ip) with α-mCC1 antibody, analyzed by 6% SDS PAGE, and immunoblotted (Ib) with α-FAS antibody to detect FAS binding to CEACAM1 and reimmunoprobed
(reIb) with α-mCC1 antibody to account for the amount of CEACAM1 in the immunopellets (top gel set). Lysates were also immunoprecipitated with α-IRβ antibody
prior to immunoblotting (Ib) with phosphotyrosine antibody (α-pTyr) and reprobing (reIb) with α-IR antibody to account for the amount of IR in the immunopellets (center
gel set). To measure total FAS content, liver lysates were analyzed by 6%–12% SDS-PAGE and immunoblotting with α-FAS antibody followed by reprobing with
α-actin antibody (α-actin) (bottom gel set). These experiments were repeated on two sets of experiments using a different mouse from each refeeding time.
B) Male mice at 2 months of age were fed ad libitum (Rand) or fasted overnight (F) and refed for 1–10 hr prior to removal of blood to determine insulin levels (top
graph) and liver and adipose tissue to assay FAS activity (center and bottom graphs, respectively). Insulin and FAS assays were performed on 3–5 mice in duplicate
and quadruplet, respectively. Values are expressed as mean ± SEM. *p < 0.05 versus fasted (0). Hepatic FAS content (bottom gel set) and its interaction with CEACAM1
(top gel set) and insulin receptor phosphorylation (center gel set) were also analyzed by Western blotting, as in (A) above.mice, insulin did not significantly decrease FAS activity in the
liver of L-SACC1 mice (Figure 5A, bottom graph).
Because wild-type (wt) and L-SACC1 mouse lines commonly
exhibited a substantial increase in insulin secretion at 7 hr of
refeeding, we then compared FAS activity in these mice at this
refeeding time. As expected, increases in insulin levels (by
w4-fold) caused an w3-fold induction of hepatic FAS protein
levels in refed (R7) wt by comparison to fasted (F) mice (Figure
5B, center gel set). Despite this increase, FAS enzymatic activ-
ity was reduced by w50% compared to fasting (Figure 5B,
graph, bar R7 versus F). This was associated with increasedCELL METABOLISM : JULY 2005IR phosphorylation (pIR) and with an w3-fold increase in the
association of CEACAM1 with FAS, as demonstrated by the
coimmunoprecipitation experiment (Figure 5B, top gel set, lane
R7 versus F). In L-SACC1 mice, however, insulin release (by
w1.5-fold) failed to induce IR phosphorylation (Figure 5B, bot-
tom gel set, lane R7 versus F) and FAS binding to CEACAM1
(Figure 5B, top gel set, lane R7 versus F), as well as to reduce
FAS enzymatic activity (Figure 5B, graph, bar R7 versus F). As
expected from hyperinsulinemia and obesity, steady-state fast-
ing FAS levels (Figure 5B, center gel set) and activity (Figure
5B, graph) were higher in L-SACC1 by comparison to wt mice.47
A R T I C L EFigure 5. The acute effect of insulin on FAS activity is abolished in the hyperinsu-
linemic L-SACC1 mouse
A) Male L-SACC1 mice at 2 months of age were subjected to a fasting/refeeding
paradigm similar to the one described in Figure 4B. At the end of fasting/refeed-
ing, blood was drawn to measure insulin levels (top graph) and the liver removed
to assay FAS activity (lower graph). Five to six mice per group were used for
each time point, and the assays were performed in duplicate or quadruplet for
insulin and FAS assays, respectively. Values are expressed as mean ± SEM.
*p < 0.05 versus fasted.
B) Two-month-old wild-type (wt) and L-SACC1 female mice were fasted (F) and
refed for 7 hr (R7), and the liver removed to determine FAS activity (graph),
content (center gel set), and its interaction with CEACAM1 (top gel set), as above.
Phosphorylation of the insulin receptor was also analyzed by immunoblotting
with α-pTyr antibody as above (bottom gel set). FAS assay was performed in
triplicate and insulin in duplicate. Values are expressed as mean ± SEM. *p < 0.05
versus fasted; **p < 0.05 versus wt fasted. SDS-PAGE analysis was repeated on
two sets of experiments using a different mouse from each refeeding time.48Refeeding L-SACC1 mice did not augment FAS content above
basal (Figure 5B, center gel, lane R7 versus F). Moreover, de-
spite comparable levels of FAS in refed wt and L-SACC1 mice,
FAS activity was lower in refed wt than L-SACC1 mice. Taken
together, the data suggest that the acute effect of insulin on
hepatic FAS activity is abolished in chronic hyperinsulinemia,
probably due to reduced ability of insulin to activate the insulin
receptor and induce CEACAM1 phosphorylation and interac-
tion with FAS.
We then examined FAS activity in the hyperinsulinemic Ob/
Ob obese mice to further investigate whether the negative
acute effect of insulin depends on the insulinemic state. As
expected from hyperinsulinemia (insulin levels w9-fold higher
than in lean mice), hepatic FAS steady-state levels (Figure 6D)
and activity (Figures 6A and 6F lanes) are higher in Ob/Ob by
comparison to their wt lean counterparts. Increases in insulin
levels upon refeeding for 7 hr (by w4-fold increase) did not
significantly decrease FAS activity in Ob/Ob as it did to wt mice
(Figure 6A, bars R7 versus F). The decrease in FAS activity in
refed wt mice was associated with increased phosphorylation
of the receptor (pIR) (Figure 6C, lane R7 versus F) and of CEA-
CAM1 (pCC1) and elevated FAS/CEACAM1 coimmunoprecipi-
tation (Figure 6B). In contrast, insulin did not increase receptor
phosphorylation in refed Ob/Ob mice (Figure 6C, lane R7 ver-
sus F). Consequently, it failed to induce CEACAM1 phosphory-
lation and its association with FAS (Figure 6B, lane R7 versus
F). Because hepatic CEACAM1 levels were unaltered in Ob/Ob
mice (Figure 6E), the data suggest that the acute effect of insu-
lin on FAS activity is abolished in hyperinsulinemia when insulin
fails to activate its receptor and phosphorylate CEACAM1.
A role for CEACAM1 in mediating the acute effect
of insulin on FAS activity
Short-term insulin treatment significantly decreased FAS activ-
ity in primary hepatocytes from wt (439.4 ± 75.27 cpm/g ver-
sus 674.2 ± 102.0; p < 0.05) but not L-SACC1 mice with liver
overexpression of the phosphorylation-defective CEACAM1
mutant (767.1 ± 160.5 cpm/g versus 678.7 ± 158.9). Because
the short-term effect of insulin on FAS activity was retained in
L-SACC1 hepatocytes even after they have been isolated from
elevated levels of insulin, a functional CEACAM1 appears to be
required for cells to respond intrinsically to acute changes of
insulin levels.
To further test this hypothesis, we assayed FAS activity in
Cc1−/− mice with null mutation of Ceacam1. As expected, CEA-
CAM1 association with FAS was abolished in the Cc1−/− mice,
as assessed by coimmunoprecipitation (Figure 7A). Increases
in insulin secretion upon refeeding overnight-fasted mice for 7
hr (Figure 7B, top graph) did not reduce hepatic FAS activity in
Cc1−/− as in wt mice (Figure 7B, bottom graph, bar R7 versus
F). This occurred in parallel to the failure of insulin to induce
insulin receptor phosphorylation (pIR) in Cc1−/−, as opposed to
wt mice (Figure 7B, top gel set, R7 versus F lanes).
However, because Cc1−/− mice are hyperinsulinemic (Figure
7B, top graph, plasma insulin levels of 538. 6 ± 49.4 in Cc1−/−
versus 207.0 ± 20.6 in wt mice, p < 0.05), it is possible that the
absence of the negative effect of insulin on FAS activity results
from the chronically elevated insulin levels. Thus, we examined
FAS activity in primary hepatocytes derived from these mice.
Insulin treatment for 15 min significantly reduced FAS activity
in wt but not in Cc1−/− hepatocytes (Figure 7C). Furthermore,CELL METABOLISM : JULY 2005
Regulation of FAS activity by insulinFigure 6. The acute effect of insulin on FAS activity is abolished in the hyperinsu-
linemic Ob/Ob obese mouse
A) Two-month-old lean (wt) and Ob/Ob obese male mice were fasted (F) and
refed for 7 hr (R7), and the liver removed to determine FAS activity. The assay
was performed in triplicate on 5–6 mice per group. Values are expressed as
mean ± SEM. *p < 0.05 versus fasted; **p < 0.05 versus wt fasted.
B) Liver lysates were immunoprecipitated (Ip) with α-mCC1 and analyzed by
immunoblotting (Ib) with α-pTyr antibody to determine phosphorylation of CEA-
CAM1 (pCC1). CEACAM1 immunopellets were also immunoblotted with α-FAS
to determine the interaction between these two proteins followed by reimmu-
noblotting (reIb) with α-mCC1 to account for the amount of CC1 in the immuno-
pellet.
C) Liver lysates were immunoprecipitated with α-IRβ antibody and analyzed for
IR phosphorylation (pIR) as in (B) above.
D and E) To determine the content of FAS and CEACAM1, liver lysates were
sequentially immunoblotted (Ib) with their respective antibodies and then with
α-actin antibody to normalize for the amount of proteins on the gel. Gels are
representatives of at least three experiments.redelivering wt but not the S503A phosphorylation-defective
Cc1 mutant by adenovirus infection (Ad) restored the acute
negative effect of insulin on FAS activity in Cc1−/− cells (Figure
7D, graph). Because infection with the adenovirus vector con-CELL METABOLISM : JULY 2005trol (Ad Luc) did not yield a decrease in FAS activity in response
to insulin, the negative effect of insulin on FAS activity in Ad-
wt Cc1 cells is specific to the wt isoform. Furthermore, insulin-
stimulated receptor phosphorylation was intact in cells trans-
duced with recombinant Ad-S503A CEACAM1 mutant (Figure
7D, bottom gel set). This emphasizes that acute regulation of
FAS activity by insulin is a postreceptor event that is mediated
by CEACAM1 phosphorylation.
Discussion
Altered fat metabolism plays an important role in the pathogen-
esis of obesity and type 2 diabetes. Since lipid metabolism
and insulin clearance in liver modulate insulin action (Bergman,
2000; Massillon et al., 1997), it is important to understand
whether they are regulated in a concerted manner. We have
shown that CEACAM1 promotes insulin internalization (Choice
et al., 1998; Formisano et al., 1995; Najjar et al., 1998) and
that inactivation of CEACAM1 in liver impairs insulin clearance,
alters fat metabolism, and leads to visceral obesity (Poy et al.,
2002b). Thus, we investigated whether CEACAM1 directly reg-
ulates lipid metabolism. We report that CEACAM1 plays a sig-
nificant role in insulin regulation of hepatic fatty acid synthesis.
In addition to its well-established chronic effect to increase
FAS mRNA levels, we describe a novel acute lowering effect
of insulin on hepatic FAS activity that is mediated by engag-
ing CEACAM1-dependent insulin signaling pathways. Gavage
feeding causes a biphasic decrease in FAS activity that mirrors
insulin secretion in fasted normoinsulinemic mice. Similarly, re-
feeding mice with regular chow increases insulin surges after
1 hr, as has been shown (Zammit and Moir, 1993), but more
significantly after 4 and 7 hr, and it causes a decrease in FAS
activity. The decrease in FAS activity depends on the ability of
insulin to induce CEACAM1 phosphorylation and binding to
FAS, as highlighted by redelivering CEACAM1 to Cc1−/− pri-
mary hepatocytes. Moreover, it occurs despite a modest eleva-
tion in FAS protein content with prolonged refeeding, especially
after 5 hr. Our data are in agreement with previous reports
demonstrating that increases in FAS mRNA transcription begin
only at about 4 hr but without elevation in FAS activity until
about 8 hr of refeeding (Iritani, 1992).
In contrast to normoinsulinemic mice, insulin did not signifi-
cantly reduce FAS activity in refed obese hyperinsulinemic
mice (L-SACC1, Cc1−/−, and Ob/Ob). This is consistent with
blunted ability of insulin to activate insulin receptors in chronic
hyperinsulinemia. Our data are in agreement with the acute
downregulatory effect of hepatic triglyceride output by insulin
and support the notion that hepatic fatty acid synthesis and
triglyceride output are tightly regulated (Lewis and Steiner,
1996; Malmstrom et al., 1998).
The physiologic distribution of CEACAM1 to the liver, as op-
posed to the adipose tissue, and the dependence of the acute
negative effect of insulin on CEACAM1 phosphorylation sug-
gest that insulin acutely decreases FAS activity to dampen lipo-
genesis in liver during refeeding. With the liver being chronically
exposed to high levels of insulin in the portal circulation (Ward
et al., 1990) that could otherwise increase lipogenesis, acute
downregulation of FAS activity could constitute a mechanism
to maintain insulin sensitivity in liver.
The relevance of FAS activity to insulin action in metabolic
control has been highlighted by the observation that treatment49
A R T I C L EFigure 7. CEACAM1 phosphorylation mediates the acute negative effect of insulin on FAS activity
A) Primary hepatocytes from wt and Cc1−/− 3-month-old mice were treated with insulin (+) or with buffer (−) for 5 min. Cell lysates were immunoprecipitated (Ip) with
α-mCC1 antibody and immunoblotted (Ib) with α-FAS antibody to detect FAS binding to CEACAM1 and reimmunoprobed with α-mCC1 antibody to account for the
amount of CEACAM1 in the immunopellets.
B) wt and Cc1−/− female mice at 2 months of age were fasted overnight (F, white bars) and refed for 7 hr (R7, dashed bars). Mice were sacrificed and the blood
removed to measure plasma insulin levels in duplicate (top graph), and the livers removed and homogenized to assay for FAS activity in triplicate (bottom graph). At
least four mice were included in each group. Values are expressed as mean ± SEM. *p < 0.05 versus fasted; **p < 0.05 versus wt fasted. Phosphorylation of the insulin
receptor was analyzed by immunoblotting α-IRβ immunoprecipitates with α-pTyr antibody and normalizing with the amount of IR in the pellet, as assessed by reprobing
(reIb) with α-IR antibody (top gel set). FAS content was assessed by immunoblotting cell lysates with α-FAS followed by reprobing with α-actin antibody to normalize
per the amount of proteins loaded (bottom gel set). These gels are representatives of three experiments.
C) Serum-starved primary hepatocytes from 3-month-old wt and Cc1−/− null mice were treated with insulin (solid bars) or buffer (white bars) for 15 min. FAS-specific
activity was assayed in triplicate. Values are expressed as mean percentage of basal ± SEM. *p < 0.05 versus buffer.
D) Primary hepatocytes from wt and Cc1−/− null mice were infected with the adenovirus vector control (Ad Luc) or carrying rat wt and S503A phosphorylation-defective
Cc1mutant (SA Cc1), treated with insulin (+) or buffer alone (−) for 15 min prior to analyzing lysates by immunoblotting (Ib) with α-rCC1 rat antibody and then with α-actin
(top gel set). One hundred and fifty microgram cell lysates were immunoprecipitated (Ip) with α-IR antibody, analyzed on SDS-PAGE, and sequentially immunoblotted (Ib)
with α-pTyr and α-IR antibody, with the latter being performed to normalize for the amount of IR (bottom gel set). FAS activity was also assayed in triplicate (graph).
Values are expressed as mean percentage of basal ± SEM. *p < 0.05 versus buffer.of obese mice with FAS inhibitors reduces body weight by reg-
ulating malonyl-CoA levels independently of leptin (Loftus et
al., 2000). Inhibiting FAS in the arcuate nucleus also reduces
food intake and promotes insulin sensitivity (Elmquist and Mar-
cus, 2003; Gao and Lane, 2003; Mobbs and Makimura, 2002;
Wortman et al., 2003), suggesting that FAS downregulation
maintains insulin sensitivity. These observations are in agree-
ment with the model proposed by our studies and emphasize
the role of de novo synthesis of fatty acids in regulating insulin
action in the brain-liver axis.
The current studies identify a new mechanism of the regula-
tion of hepatic fat metabolism by insulin. The mechanism impli-50cates CEACAM1 phosphorylation by the insulin receptor and
its cellular uptake and binding to FAS. Increased redistribution
of CEACAM1 in the cytoplasm of hepatoma cells in response
to insulin is consistent with increased CEACAM1 endocytosis
as part of the insulin endocytosis complex (Choice et al., 1998).
This demonstrates the intertwined molecular mechanism of the
effect of CEACAM1 on insulin and fat metabolism. Because
FAS binding to CEACAM1 requires Tyr488 phosphorylation, as
does the formation of CEACAM1/insulin receptor complex
(Choice et al., 1998), it is possible that FAS binding to CEA-
CAM1 increases simultaneously with the complex dissociation
from the receptor. This suggests that CEACAM1 is not directlyCELL METABOLISM : JULY 2005
Regulation of FAS activity by insulininvolved in the postinternalization receptor trafficking events to
a large extent, including receptor recycling, as we have pre-
viously reported (Li Calzi et al., 1997). Persistent CEACAM1
localization in the cytoplasmic compartment even after its
phosphorylation and association with FAS were significantly re-
duced suggests that it may be involved with other cellular
events. Whether CEACAM1 eventually recycles back to the
plasma membrane is not known and analysis of its metabolism
and function is beyond the scope of these current studies.
Nonetheless, the data provide compelling evidence that CEA-
CAM1 interacts with fatty acid synthase to tightly regulate fat
metabolism and preserve insulin sensitivity in liver. In light of
the dependence of CEACAM1/FAS interaction on insulin-
induced CEACAM1 internalization, and the primary role of this
mechanism in insulin clearance, the current data demonstrate
that CEACAM1 is at the intersection of the pathways regulating
insulin and fat metabolism in liver.
Experimental procedures
Generation of the Ceacam1 null (Cc1−/−) mouse
Exons 1 and 2 of Ceacam1a were replaced by a GK-neor cassette using
homolgous recombination in ES cells to eliminate translation initiation
(Nédellec et al., 1995). Generation of knockout mice was according to stan-
dard procedures (Hemmila et al., 2004). Animals were kept in a 12 hr dark-
light cycle and fed standard chow ad libitum, unless otherwise indicated.
Whole blood was drawn from anesthetized mice at indicated time points
from retro-orbital sinuses to determine plasma insulin levels by radio-
immunoassays (RIA) (Linco Research). All procedures are approved by the
Institutional Animal Care and Utilization Committee.
Cell culture
MDA-MB 468 human breast cancer cells were maintained in Leibovitz’s
L-15 media (Invitrogen) at 37°C in a CO2-free incubator, and H35-BT rat
hepatoma cells (Taub et al., 1987) and their H4-II-E derivatives in Dulbecco-
Modified Eagle’s Medium (DMEM, Mediatech) and RPMI-1640 (Mediatech),
respectively, at 37°C in a 5% CO2 incubator. All media were supplemented
with 10% fetal bovine serum (FBS, Mediatech), 100 U/ml penicillin, 10 g/ml
streptomycin, and 1% glutamine (Invitrogen), except for the medium of
H35-BT, which was supplemented with 5% FBS and 5% new born calf
serum.
Primary hepatocytes
As described in Poy et al. (2002b), male mice were anesthetized with so-
dium pentobarbital (30 g/g body weight). Hepatocytes were isolated by a
two-stage collagenase perfusion through the portal vein (Hanks/EGTA [0.5
mM] and 1 mg/ml collagenase D [Roche] in L-15 media supplemented with
glucose [1 mg/ml]). The viability of hepatocytes was determined by Trypan
Blue dye exclusion. Cells were plated at 4.5 × 106 cells per 100 mm dish in
10 ml DMEM, supplemented with FBS (10% v/v) and penicillin/streptomycin
(1% v/v) at 37°C. Cultures were refed with fresh DMEM medium after a
3 hr attachment period (Ruch and Klaunig, 1988).
GST pull-down assay
Unless indicated otherwise, GST-CEACAM1 fusion peptides were de-
scribed previously (Najjar et al., 1995). The Ser503 to Asp mutation (S503D)
was introduced by PCR. Primer sequences are available upon request. GST
fusion peptides (10 g) were phosphorylated by baculovirus-purified IRKβ
(Biomol, 1 U) or GST-tagged (Calbiochem, 1 U) in the presence of 70 Ci
[γ-32P] ATP, bound (60 min at 4°C) to equal amounts of MDA-MB 468 cell
lysates, or 1 g purified His-tagged FAS (Joshi and Smith, 1993; Joshi et
al., 1997). Pellets were washed in HNTG buffer containing 0.5% Triton and
analyzed by electrophoresis. Standard Western blotting techniques with
anti-FAS antiserum were employed.
Western blotting
For coimmunoprecipitation, cells were treated with 100 nM insulin for 0–90
min unless otherwise indicated, prior to lysis and protein immunoprecipita-CELL METABOLISM : JULY 2005tion (Najjar et al., 1995). Mice were fasted and refed and the tissues re-
moved and lysed. Following lysis, proteins (400 g) were subjected to coim-
munoprecipitation (Choice et al., 1998). In these experiments, a monoclonal
HA4 c19 (Hybridoma Bank, Iowa) or an anti-mouse polyclonal antibody
against BGP1 (α-mCC1; Ab-231) (Sadekova et al., 2000) was used to immu-
noprecipitate the rat and the mouse protein, respectively. Following immu-
noprecipitation, proteins were immunoblotted with α-FAS polyclonal anti-
body to detect the amount of FAS in the CC1 immunopellet, and with α-76
Ex/α-CC1 rat antibody (Poy et al., 2002a) or α-mCC1 to normalize for the
amount of CEACAM1 in the immunopellet.
For phosphorylation, 1 g of His-tagged FAS was phosphorylated by
preactivated GST-IRKβ (1 U) in the presence of [γ-32P] ATP at RT for 10–60
min in phosphorylation buffer (above) prior to analysis by 6% SDS-PAGE
and autoradiography. Insulin-treated cells or mouse livers were lysed, and
200 g of lectin-purified proteins were immunoprecipitated with antibodies
against CEACAM1 (α-CC1) or the β subunit of the insulin receptor (α-IRβ)
(Santa Cruz) prior to analysis by SDS-PAGE and immunoblotting with
α-phosphotyrosine antibody (α-pTyr) (Upstate Biotechnology Inc.) to exam-
ine the phosphorylation state. The amount of incorporated phosphotyrosine
was normalized by the amount of proteins in the immunopellet, which was
in turn determined by reprobing with α-CC1 or α-IRβ antibody.
To determine the protein content, 75 g lysates were analyzed directly
by SDS-PAGE followed by sequential immunoblotting with their antibodies
and then with α-actin (Sigma-Aldrich) to normalize for the amount of pro-
teins loaded on the gel.
FAS enzymatic activity
Two-month-old male normal mice were fasted overnight (from 1700 to 0700
hr the next day) and refed regular chow for 1–10 hr or were given glucose
(2 g/Kg body weight) by oral gavage for 0–120 min. Two-month-old male
Ob/Ob mice (Jackson Laboratories) and L-SACC1 and Cc1−/− female mice
were subjected to a similar fasting/refeeding paradigm. Following refeeding,
mice were sacrificed, and their livers removed and homogenized in buffer
containing 20 mM Tris (pH 7.5), 1 mM EDTA, 1 mM DTT, and phosphatase
and protease inhibitors (Najjar et al., 1995). Primary hepatocytes or H35-BT
cells were grown in DMEM complete medium at a density of 4.5 × 106 cells/
10cc plate, serum-starved overnight, treated with 100 nM insulin for 0–90
min at 37°C, and lyzed, as above. The homogenate was centrifuged at
12,500 × g for 30 min at 4°C and FAS activity assayed in the postmitochon-
drial supernatant (Hennigar et al., 1998). Briefly, lysates were incubated at
37°C for 20 min with 166.6 M acetyl-CoA, 100 mM potassium phosphate
(pH 6.6), 0.1 Ci [14C] malonyl-CoA, 25 nmol malonyl-CoA in the absence
(negative controls) or presence of 500 M NADPH. The reaction was
stopped with 1 ml 1:1 chloroform:methanol solution and mixed at room
temperature for 30 min. Following centrifugation at 12,500 × g for 20 min,
the supernatant was vacuum-dried, and the pellet resuspended in 200 l
of water-saturated butanol. Two hundred microliters ddH2O was added fol-
lowed by vortexing and quick spinning for 1 min to remove the upper layer
for re-extraction. Both butanol samples were pooled and washed with
ddH2O. The butanol layer was moved, dried, and counted for (Giaccari et
al., 1998) incorporation. Protein concentrations of cell lysates were mea-
sured by the Bio-Rad protein assay. FAS activity was calculated as cpm of
[14C] incorporated/g of cell lysates.
His-tagged baculovirus-purified CEACAM1 (Phan et al., 2001) was phos-
phorylated by buffer alone or GST-tagged IRKβ at 25°C for 60 min in the
presence of 70 Ci [γ-32P] ATP. One picamole of His-tagged FAS (Joshi and
Smith, 1993) was then added and the reaction mixed at 4°C for 60 min.
FAS activity was assayed and normalized per activity in control samples
without CEACAM1.
Confocal microscopy
H4-II-E rat hepatoma cells were serum-starved overnight and then incu-
bated in DMEM medium (Invitrogen) containing 0.24 mg/ml of α-CC1/HA4
monoclonal antibody at RT for 2 hr (Lamaze et al., 2001; Oyarce et al.,
2001). Cells were rinsed with PBS and fixed with cold methanol either im-
mediately or following treatment with 100 nM of insulin at 37°C for different
time periods. Cells were then blocked with 0.25% BSA and incubated at
RT for 2 hr with polyclonal α-FAS antibody (2 g/ml). Following incubation
with the FAS antibody, cells were incubated with goat anti-mouse FITC and
goat anti-rabbit Cy3 conjugated secondary antisera (Caltag Laboratories)51
A R T I C L Eat RT for 1 hr and analyzed using an Olympus microscope coupled to a
Bio-Rad Radiance 2100 confocal scanning laser. To label IRS-2, serum-
starved cells were treated with insulin, fixed with cold methanol, and
blocked in 25% BSA, as above. A rabbit polyclonal antibody against IRS-2
(Upstate Biotechnology) was added at 1/10–1/100 dilutions for an overnight
incubation prior to green FITC labeling and confocal microscopy.
Quantitation of proteins and statistical analysis
Autoradiograms were scanned on an imaging densitometer (Bio-Rad), and
the proteins were quantitated with SPECTRA MAX Plus (Molecular Devices)
using the SoftMAX Pro Macintosh software program (Molecular Devices).
Data were analyzed with Prism3 software (GraphPad Software, Inc.) using
t test analysis. p values of less than 0.05 were considered statistically signif-
icant.
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